about
Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative EffortMinimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapiesDHRS9 is a Stable Marker of Human Regulatory Macrophages.Single cell tracking of gadolinium labeled CD4+ T cells by laser ablation inductively coupled plasma mass spectrometry.In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies.Human regulatory macrophages as a cell-based medicinal product.Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation.Clinical management of patients receiving cell-based immunoregulatory therapy.Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I).Now or never? The case for cell-based immunosuppression in kidney transplantation.Peer Review in Transplantation.Hurdles in therapy with regulatory T cells.The Mononuclear Phagocyte System in Organ Transplantation.Transplant survival: knowing the future.Langerhans cells promote early germinal center formation in response to Leishmania-derived cutaneous antigens.MITAP-compliant characterization of human regulatory macrophages.Tracking of human cells in mice.Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.Pharmacovigilance in Europe.DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance.First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver TransplantationData sharing.Cryopreservation of immature monocyte-derived dendritic cells results in enhanced cell maturation but reduced endocytic activity and efficiency of adenoviral transduction.Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible.Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation.Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells.Age and gender leucocytes variances and references values generated using the standardized ONE-Study protocol.Human transplant acceptance-inducing cells suppress mitogen-stimulated T cell proliferation.European Reflections on New Indications for Extracorporeal Photopheresis in Solid Organ Transplantation.Early Enrichment and Restitution of the Peripheral Blood Treg Pool Is Associated With Rejection-Free Stable Immunosuppression After Liver Transplantation.Passenger Leucocyte Syndrome.TIGIT iTregs elicited by human regulatory macrophages control T cell immunityCutting Edge: Immunological Consequences and Trafficking of Human Regulatory Macrophages Administered to Renal Transplant RecipientsComparison of two column agglutination tests for red blood cell antibody testingCould treatment with neohepatocytes benefit patients with decompensated chronic liver disease?Somatic Cell-based TherapyFlow Cytometry in TransplantationQuantification of mRNA Expression by RT-qPCRHLA typingDonor malignancies
P50
Q26773299-C9AE479E-04D3-4671-88A5-26FACD31EF70Q28596281-F85FBE76-FC15-4066-AAEA-D2698160DEDBQ30491942-0B42DBBB-712C-44C4-B22C-53FEC8EC5302Q35002558-2D1BCE9E-A176-472A-B3B5-4107A6575F64Q35184210-A4CA1FD9-828E-4434-BE34-A10A29568B42Q37970215-3C0D024D-3D91-44CA-85CA-4C661F910C60Q38025841-4EA11FAB-6EF6-4779-B4BA-E2F906BA8B0FQ38201742-094DEDE6-13EB-4DB2-969D-791FB684FE1BQ38292656-97F33FA0-E9D0-4C5A-B9F7-09DD1D29D32DQ38367524-8F2D37B9-3D41-4291-BAD1-E28718795849Q38574090-8BD11430-23B6-4AC8-9D78-16BB495FF6AEQ38583881-4CF8129B-DFEC-4277-9FBD-5F721BBBE81CQ38646389-12D583F1-26E9-40B7-A7C4-565454FF06F8Q38838382-E368CA59-DE10-4DB8-937D-D79B9FE01674Q39152557-94055EAA-C1DA-47AE-9D9E-9A36B625C75CQ39329676-7E55B213-C663-4EC2-BB6E-BDCB4BCC815BQ39990080-8C201A1F-B422-4F41-9E19-5A0B06600A11Q40491652-10035B94-5315-49FB-BC8F-B4D1B31FE0EAQ41451399-FAF780E8-0317-4381-9D64-B5F6E9A5B8C2Q41925366-E11BBEAB-4730-4998-A848-F33AD5BFBBA8Q41950774-4F6824CB-769A-4678-A269-018ADE14AC69Q42611565-91153554-B6BF-4982-B251-A27A441C1935Q43888551-E671F2AE-44B6-4CDC-A829-FEC3C2D7F308Q46129947-98410427-1432-4F8A-A65C-8BE5EFCACE97Q46523918-F88626EC-061D-4958-9FF7-19A6BC357FABQ46523931-B6965F55-2537-418B-9A90-B82F6B28030DQ48818805-3770DBE7-0460-49B4-BCD6-43ED9F0540F7Q51735795-E88C0B66-181F-42FC-95D5-DE2061C03E85Q52583132-FCA33F63-60A4-46C4-8510-F50C67C9CA0AQ52850813-CA9BA321-3B85-4A6C-AB6F-34D54C9BBD68Q54032406-F0A6CCA9-4C2E-4FCE-BFCF-56F5920FDFC2Q56967224-9CEFF35D-A7A4-4AAC-832E-7197DD30D21BQ56989328-CB8485C8-3EC1-495C-98F7-DAF64183618EQ60924989-32BA5E2B-A8A1-478C-82D9-F076E8ABCCE8Q80854973-487DBA95-CEF2-43C0-9916-C34F00C31C39Q85278271-E9458601-AF0D-461C-BE76-2A011F5014F0Q85537703-51AB474D-8F13-4BB3-9308-D3E1E97603DFQ86350526-893D4631-4552-4C92-982A-55C2F7E2B4A1Q86354721-2E8E6A22-D984-4389-8CC6-2D718457745DQ86657185-B8A3E77D-D6B8-4A0A-9841-60705CF77F26
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James A Hutchinson
@ast
James A Hutchinson
@en
James A Hutchinson
@es
James A Hutchinson
@nl
type
label
James A Hutchinson
@ast
James A Hutchinson
@en
James A Hutchinson
@es
James A Hutchinson
@nl
prefLabel
James A Hutchinson
@ast
James A Hutchinson
@en
James A Hutchinson
@es
James A Hutchinson
@nl
P106
P1153
35463294900
56672404400
P21
P31
P496
0000-0002-1199-4210